Despite a strong association of IFNγ with murine models of colitis, the clinical response of fontolizumab, a humanized anti-IFNγ specific antibody, in IBD patients was not detectable although improved inflammatory scores were observed (9–11, 57–60). Here, IFNG is linked to inflammatory bowel disease.